Poolbeg Pharma Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Poolbeg Pharma disminuyan en un 13.1% al año. Se prevé que el BPA disminuya en un 11.7% al año.

Información clave

-13.1%

Tasa de crecimiento de los beneficios

-11.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	19.6%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	20 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12

Previsiones de crecimiento de beneficios e ingresos

AIM:POLB - Estimaciones futuras de los analistas y datos financieros pasados (GBP Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	N/A	-6	-6	-5	2
12/31/2024	N/A	-6	-6	-6	2
6/30/2024	N/A	-4	-5	-4	N/A
3/31/2024	N/A	-4	-5	-4	N/A
12/31/2023	N/A	-4	-5	-4	N/A
9/30/2023	N/A	-4	-5	-5	N/A
6/30/2023	N/A	-5	-5	-5	N/A
3/31/2023	N/A	-5	-5	-5	N/A
12/31/2022	N/A	-5	-5	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que POLB siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que POLB siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que POLB siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de POLB crezcan más rápidamente que el mercado de UK.

Ingresos de alto crecimiento: Se prevé que POLB no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de POLB se prevé que sea elevada dentro de 3 años.

Poolbeg Pharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Poolbeg Pharma plc Announces U.S. Patent Office Grants U.S. Immunomodulator I Patent

Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application

New minor risk - Financial data availability

Executive Chairman of The Board recently bought UK£97k worth of stock

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome

High number of new and inexperienced directors

Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully

Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Poolbeg Pharma Receives Notice of Allowance from the Japanese Patent Office in Relation to its Immunomodulator I Patent Application

Poolbeg Pharma plc Announces Immunomodulator I Patent Opposition Withdrawal

New minor risk - Share price stability

Poolbeg Pharma plc Announces Significant Breakthrough in Its World First Influenza Artificial Intelligence Programme with Cytoreason

Less than half of directors are independent

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Board Changes

Poolbeg Pharma plc Announces Strategic Expansion of Polb 001 into Oncology

Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial

Poolbeg Pharma Identifies Novel RSV Drug Candidates

Poolbeg Pharma plc Announces POLB 001 LPS Human Challenge Clinical Trial Successfully Completed

Poolbeg Pharma Announces Completion of Influenza AI Model Build

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma plc Receives Ethics and Competent Authority Approval to Commence Its Lipopolysaccharide (Lps) Human Challenge Clinical Trial for Polb 00

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Poolbeg Pharma plc Provides Project Update for AI Model of RSV Data

Poolbeg Pharma PLC Provides Update on POLB 001 Clinical Development

No independent directors

Poolbeg Pharma plc Provides an Update on the Strengthening of Its Intellectual Property for Its Asset POLB 002

Poolbeg Pharma PLC to Report Q4, 2021 Results on Mar 03, 2022

Poolbeg Pharma PLC has completed an IPO in the amount of £25 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento